Curzion Pharmaceuticals Acquired by Horizon Therapeutics
DUBLIN — April 2, 2020 — Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it has acquired Curzion Pharmaceuticals, Inc., a privately held development-stage biopharma company, and its development-stage oral...
Athersys begins Phase I trial for ATHX-105 for treatment of obesity
News | 07. 25. 2007
Athersys, Inc., a wholly owned subsidiary of BTHC VI (OTC Bulletin Board: BVIC), announced today that it has initiated a Phase I clinical trial in the United Kingdom for ATHX-105, the company’s oral, selective 5HT2c receptor agonist for treating obesity.